Akebia Therapeutics (AKBA) Cost of Revenue (2013 - 2026)

Akebia Therapeutics (AKBA) has 11 years of Cost of Revenue data on file, last reported at $12.3 million in Q1 2026.

• Cost of Revenue for Q1 2026 came in at $12.3 million, up 61.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $44.1 million (down 48.83% YoY), and the FY2025 annual result was $39.5 million, down 37.54% from the prior year.
• Cost of Revenue declined to $12.3 million in Q1 2026 per AKBA's latest filing, from $12.5 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $47.4 million in Q4 2024 and troughed at -$12.4 million in Q4 2022.
• A 5-year average of $14.0 million and a median of $12.3 million in 2026 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2022 and 2023: Cost of Revenue sank 207.37% in 2022, then soared 250.05% in 2023.
• A 5-year view of Cost of Revenue shows it stood at -$12.4 million in 2022, then soared by 250.05% to $18.7 million in 2023, then soared by 153.94% to $47.4 million in 2024, then slumped by 73.55% to $12.5 million in 2025, then retreated by 1.95% to $12.3 million in 2026.
• Business Quant data shows AKBA's Cost of Revenue at $12.3 million in Q1 2026, $12.5 million in Q4 2025, and $9.4 million in Q3 2025.